MedTrace Logo

Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)

NCT01918761 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2019-12-30

Study results available
· View outcomes & findings →

Summary

To identify a dose of dacomitinib in combination with pemetrexed that is safe and tolerated as determined by the incidence of DLTs (dose limiting toxicities).

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Dacomitinib, Pemetrexed

Pemetrexed 500mg/m2 i.v (q21d) Dacomitinib 45mg orally (continuous)

Sponsors & Collaborators

  • Central European Cooperative Oncology Group

    lead OTHER

Principal Investigators

  • Christoph C Zielinski, Univ. Prof. · Univ Clinic for Internal Medicine I, Dep of Oncology, Medical University of Vienna

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-30
Primary Completion
2016-09-15
Completion
2016-09-15

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01918761 on ClinicalTrials.gov